Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, IL, USA.
J Urban Health. 2011 Feb;88 Suppl 1(Suppl 1):144-55. doi: 10.1007/s11524-010-9476-y.
Individuals with asthma living in the inner city experience increased asthma morbidity and mortality compared to the US average. The Controlling Asthma in America's Cities Project's Chicago site used a multifaceted approach to improve asthma care. The diverse scope of this project's interventions necessitated the use of novel methods to assess the effect of these interventions on the entire study area. Asthma-related medication-dispensing data were obtained from a large pharmacy chain for prescriptions filled in calendar years 2004-2006 for all individuals aged 5-17 years living in Chicago who filled at least four asthma-related medications within a 12-month period. Inhaled corticosteroid (ICS) use was considered inadequate if an individual had four or more dispensings of a short-acting beta-agonist without at least four dispensings of an ICS agent. Logistic regression was used to compare adequate ICS use in individuals within the intervention area with ICS use in the remainder of the city, after controlling for gender, insurance status, race, and poverty. A significant difference in adequate ICS use was found in years 2 (2005) and 3 (2006) of the project for individuals aged 5-9 in the intervention area (odds ratios for adequate ICS use-year 2, 1.26; CI, 1.04-1.53, p = 0.04; year 3, 1.30; CI, 1.08-1.55, p = 0.008) compared to individuals aged 5-9 in the remainder of the city. There was no similar significant difference in the 10-17 age group. These findings suggest an effect of a large multifaceted asthma intervention in improving medication use in the targeted age group. This methodology might also prove useful in the future for assessing the effect of similar interventions.
与美国平均水平相比,居住在市中心的哮喘患者经历了更高的哮喘发病率和死亡率。“控制美国城市哮喘项目”的芝加哥站点采用了多方面的方法来改善哮喘护理。该项目干预措施的多样性需要使用新的方法来评估这些干预措施对整个研究区域的影响。从一家大型连锁药店获得了 2004-2006 年期间所有年龄在 5-17 岁之间的居住在芝加哥的个人的哮喘相关药物配药数据,这些人在 12 个月内至少配了四种哮喘相关药物。如果一个人在没有至少四种吸入皮质激素(ICS)药物的情况下,配了四种或更多种短效β-激动剂,那么就认为其 ICS 使用不足。使用逻辑回归比较了干预区和城市其余地区的个人在控制性别、保险状况、种族和贫困后使用适当的 ICS 的情况。在项目的第 2 年(2005 年)和第 3 年(2006 年),干预区年龄在 5-9 岁的个人中发现了适当的 ICS 使用差异(适当的 ICS 使用的优势比,第 2 年为 1.26;置信区间,1.04-1.53,p=0.04;第 3 年为 1.30;置信区间,1.08-1.55,p=0.008),与城市其余地区年龄在 5-9 岁的个人相比。在 10-17 岁年龄组中没有类似的显著差异。这些发现表明,大型多方面哮喘干预措施的效果改善了目标年龄组的药物使用。这种方法在未来评估类似干预措施的效果时也可能证明是有用的。